Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms COVID-19 Bivalent Vaccine(Original/Omicron BA.1), Spikevax bivalent Original/Omicron BA.1, スパイクバックス(2価:起源株/オミクロン株BA.1) |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (21 May 2021), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | JP | 21 May 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | - |
Not Applicable | 292 | (feuprwftnn) = uuhkunhbrw pflytxnkdv (ygvrdarjrn ) | - | 02 Jun 2022 | |||
(feuprwftnn) = hckpackyxv pflytxnkdv (ygvrdarjrn ) | |||||||
Not Applicable | - | BNT162b2 mRNA vaccine | tyuotnnwov(jqsriaoffe) = pwzkxokmuu zflpigewjk (sykmyjsemt ) | - | 12 May 2022 | ||
tyuotnnwov(jqsriaoffe) = kkjplxftuy zflpigewjk (sykmyjsemt ) | |||||||
Not Applicable | 93 | nshmdtisdw(hexahgvudl) = kasdvmfccn rhfqmgndpd (qgyvuwwukg ) | - | 02 Jun 2022 | |||
Not Applicable | 56 | hwwlnznrua(mllaqzjufz) = CSU onset or relapse after long term remission, following COVID-19 vaccination, could be expected with all vaccines utilized in the Greek population vaccination. It is more common in female patients. Prognosis of CSU was favorable, with only 4/56 patients presenting with CSU after a 6-month follow-up. bsubnaasqm (wkzyjpdfuc ) | - | 11 Oct 2023 | |||
Not Applicable | - | BNT162B2 mRNA vaccine | (fwkhlkombu) = uaqgdsmkqe azdwgqmnps (mewvnscczi, 2.1 - 2.4) View more | Positive | 26 Aug 2022 | ||
(fwkhlkombu) = pvzmtrqfmr azdwgqmnps (mewvnscczi, 2.4 - 2.7) View more |